Selected Consolidated Data
For a reconciliation of GAAP to non-GAAP figures, refer to this page.

Non-GAAP Net Income (in millions) Edwards has consistenly grown net income while investing in new growth opportunities.		R&D Expense (in millions) Edwards continues to invest in research and development to fuel its new product pipeline.
Non-GAAP Free Cash Flow (in millions) Edwards' generates strong free cash flow, reflecting solid operating performance and consistent working capital management. This is calculated as cash flow from operating activities minus capital expenditures.		Net Sales (in millions) In 2006, Edwards' net sales exceeded $1 billion for the first time in the company's history. Approximately eighty-five percent of the company's sales come from products in leadership positions.
Stock Performance vs. Selected Indices Since 2001, Edwards' stock price has increased eightly six percent–outperforming the broader market and its medical products peer group.		Gross Profit Margin (gross profit as % of net sales) Sales of higher margin, physician-preference products and the exit from lower margin businesses are driving continued expansion of Edwards' gross profit margin.